๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12479 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 24 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,479
Total on CTIS
full historical archive
743
Phase III
within the shown window
Top member states
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531
Narrow the register
Phase
Phase I 555 Phase I/II 212 Phase II 730 Phase III 743 Phase IV 260
Lead sponsor
AstraZeneca AB 63 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531 Belgium 431 Czechia 331
All 28 states

Trials in this register

2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase IV
Randomized clinical trial to assess the efficacy and safety of a strategy for primary prevention of cardiovascular disease in patients with inflammatory rheumatic diseases based on the use of carotid ultrasound.
2025-521086-28-00CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritiโ€ฆ
Instituto De Investigacion Marques De Valdecilla
Cardiovascular Diseases
Spain
03/10/2025
Phase II
A Phase IIb, Multicenter, Double-Blind, Placebo-Controlled Induction Study with an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients with Moderately to Severely Active Ulcerative Colitis
2025-520690-39-00Moderately to Severely Active Ulcerative Colitis (UC)
Genentech Inc.
Digestive System Diseases
France, Italy, Czechia, Poland, Germany
03/10/2025
Phase III
A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study
2024-516576-15-00metastatic breast cancer
Centre Regional Lutte Contre Le Cancer
Neoplasms
France
03/10/2025
Phase II
A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Brutonโ€™s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)
2025-521088-10-00Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLLโ€ฆ
Nurix Therapeutics Inc.
Neoplasms
France, Italy, Hungary, Poland
02/10/2025
Phase II
Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA trial
2024-519479-24-00metastatic colorectal cancer
Fondazione GONO G.I.
Neoplasms
Germany, France, Italy, Spain
02/10/2025
Phase II
CRYOBI study - A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious active cryoglobulinemia vasculitis refractory or intolerant to Rituximab
2023-508930-33-00Non-infectious active cryoglobulinemia vasculitis who are eโ€ฆ
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
02/10/2025
Phase IV
The DALBA-study Introduction of the antibiotic dalbavancin in orthopaedic surgery โ€“ an evaluation of: โ€ข Health economic costs โ€ข Patient-reported outcomes on quality of life โ€ข Local bone and soft tissue concentrations โ€ข Effect on the gut microbiome A randomised controlled study of dalbavancin versus standard antibiotic treatment of Gram-positive periprosthetic joint infections.
2025-522088-13-00Periprosthetic joint infection
Region Midtjylland
Bacterial Infections and Mycoses
Denmark
02/10/2025
Phase II
A phase II randomized clinical trial of Tarlatamab as maintenance treatment after sequential chemo-radiotherapy vs sequential chemo-radiotherapy as standard treatment for limited stage SCLC patients not eligible for concurrent chemo-radiotherapy. MERLIN GECP 24/01
2024-515201-26-00Small cell lung cancer (SCLC)
Fundacion GECP
Neoplasms
Spain
02/10/2025
Phase III
A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of Intravenous Brincidofovir versus Intravenous Cidofovir for Treatment of Adenovirus Infection in Pediatric and Adult Subjects After Allogeneic Hematopoietic Cell Transplantation (allo HCT)
2025-521903-28-00Adenovirus viremia
Symbio Pharmaceuticals Ltd.
Virus Diseases
Germany, Italy, France, Spain, Portugal
02/10/2025
Phase II
AcSรฉ HER2_Widening treatment options among adult patients with HER2-overexpressing or mutant solid cancers
2025-522169-31-00Adult Patients with HER2-IHC3+ selected solid cancers (endoโ€ฆ
Unicancer
Neoplasms
France
01/10/2025
Phase III
The effect of a superficial parasternal intercostal plane block in cardiac surgical patients undergoing conventional median sternotomy: a multicentric, double-blind, prospective, randomized controlled superiority trial.
2025-522135-34-00Patients undergoing cardiac surgery through conventional meโ€ฆ
UZ Leuven
Anesthesia and Analgesia
Belgium
01/10/2025
Phase II
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-521278-32-00Idiopathic Pulmonary Fibrosis (IPF)
Mediar Therapeutics Inc.
Immune System Diseases
Croatia, Ireland, Netherlands, Spain, France, Belgium
01/10/2025
Phase I
A first-in-human, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.
2025-521658-40-00Atopic dermatitis
Egle Therapeutics
Skin and Connective Tissue Diseases
Germany, Bulgaria, Poland
01/10/2025
Phase IV
Heart rate control: Betablockers or Ivabradine therapy before cardiac computed tomography
2025-522741-21-00ischemic heart disease
Region Midtjylland
Cardiovascular Diseases
Denmark
01/10/2025
Phase I/II
An open-label, Phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic graft versus host disease (cGVHD).
2024-511508-18-00Chronic graft versus host disease.
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
France, Italy, Belgium, Spain, Netherlands, Germany
30/09/2025
Phase I
Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)
2024-515903-21-00Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen Inc.
Neoplasms
France, Germany, Spain, Greece, Hungary, Italy
30/09/2025
Phase I/II
A single-arm, open-label, phase I/II clinical trial of autologous hematopoietic stem and progenitor cells (HSPCs) genetically modified with a lentiviral vector (LVV) encoding for the human programmed death-ligand 1 (hPD-L1) complementary deoxyribonucleic acid (cDNA) for the treatment of patients with type 1 diabetes (T1D) at recent onset and with residual ฮฒ-cell function (Immunostem)
2025-521304-21-00Type 1 diabetes
Altheia Science S.r.l.
Nutritional and Metabolic Diseases
Italy
30/09/2025
Phase II
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease
2024-519190-19-00Alzheimerโ€™s Disease
Merck Sharp & Dohme LLC
Nervous System Diseases
Spain, Belgium, Netherlands
30/09/2025
Phase II
A Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical Allodynia
2024-517304-12-00Mechanical allodynia
Pharmnovo AB
Nervous System Diseases
Spain, Czechia
30/09/2025
Phase IV
A phase IV study to investigate the immunogenicity of the Seqirus licensed MF59 adjuvanted zoonotic influenza vaccine (H5N8) in adults previously vaccinated in 2009 with the Matrix M adjuvanted virosomal influenza (H5N1) vaccine compared to H5 naรฏve adults.
2025-522593-36-00Virus Diseases
Helse Bergen HF
Virus Diseases
Norway
30/09/2025
Phase II
A randomised, double-masked, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of oral BI 1815368 in participants with centre-involved diabetic macular edema for 48 weeks of treatment (THULITE)
2024-520384-14-00Centre-involved diabetic macular edema
Boehringer Ingelheim International GmbH
Eye Diseases
Germany, Slovakia, Poland, Hungary, Czechia
30/09/2025
Phase II
RANDOMIZED CONTROLLED STUDY COMPARING SUFENTANIL AND KETAMINE INTRANASALLY IN THE MANAGEMENT OF SEVERE ACUTE TRAUMA-RELATED PAIN IN CHILDREN
2025-521075-31-00SEVERE ACUTE TRAUMA-RELATED PAIN
Fondation Lenval Nice
Anesthesia and Analgesia
France
30/09/2025
Phase I
IMAGINE 1
2025-522290-11-00Cholangiocarcinoma, pancreatic cancer, colo-rectal cancer
Karolinska University Hospital
Digestive System Diseases
Sweden
30/09/2025
Phase I
FT819 in B-cell Mediated Autoimmune Diseases
2024-517397-25-00B-cell Mediated Autoimmune Diseases
Fate Therapeutics Inc.
Immune System Diseases
France, Sweden, Germany
30/09/2025
Phase II
Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
2023-504439-42-01alcohol dependence
Hospital Universitario 12 De Octubre
Behavioral Disciplines and Activities
Spain
30/09/2025
Phase II
Pembro-FLASH - Phase II trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classic Hodgkin Lymphoma
2022-501458-13-01Advanced Stage of Classic Hodgkin Lymphoma
University Of Cologne
Neoplasms
Germany
30/09/2025
Phase III
A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)
2024-518210-81-00Advanced Hepatocellular Carcinoma
AstraZeneca AB
Neoplasms
Italy, Germany, France, Poland, Spain, Netherlands
30/09/2025
Phase II
Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT)
2024-519261-21-00Desmoplastic small round cell tumor
Italian Sarcoma Group
Neoplasms
Spain, Italy
30/09/2025
Phase IV
A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease (AEOLUS)
2025-521268-37-00Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Netherlands, Hungary, France, Germany, Austria, Spain, Poland, Sweden, Italy, Denmark
29/09/2025
Phase III
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physicianโ€™s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)
2025-520582-51-00Hormone receptor positive breast cancer
Merck Sharp & Dohme LLC
Neoplasms
Greece, Poland, France, Italy, Spain, Hungary, Germany
29/09/2025
Phase I
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies
2025-521600-21-00mature B-Cell malignancies
Beigene Ltd.
Neoplasms
France, Italy
29/09/2025
Phase I
A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.
2025-521916-20-00Cancer
Eli Lilly & Co.
Neoplasms
Spain, France
29/09/2025
Phase I/II
A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial of Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in Participants with Advanced or Metastatic Non-small Cell Lung Cancer whose Tumors Express PD-L1 with Tumor Proportion Score โ‰ฅ50% Without Actionable Genomic Alterations
2024-519671-26-00Advanced or Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo Inc.
Neoplasms
Spain, France, Italy
29/09/2025
Phase III
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)
2025-521627-78-00Neoplasms, Lung
Glaxosmithkline Research & Development Limited
Neoplasms
Hungary, France, Portugal, Greece, Sweden, Ireland, Poland, Bulgaria, Romania, Finland, Italy, Germany, Spain
29/09/2025
Phase II
Testosterone supplementation in patients in best supportive care: impact on quality of life.
2025-522023-10-00Androgen deficiency, palliative care
Institut Jules Bordet
Neoplasms
Belgium
29/09/2025
Phase III
APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
2024-520407-27-00X-Linked Protoporphyria (XLP), Erythropoietic Protoporphyriโ€ฆ
Disc Medicine Inc.
Nutritional and Metabolic Diseases
Germany, Ireland, Spain, France, Norway, Netherlands, Sweden, Belgium, Italy
29/09/2025
Phase I
Multiple-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Participants.
2025-523419-12-00No medical condition.
Laboratorios Leon Farma S.A.
Not possible to specify
Portugal
29/09/2025
Phase III
STOP-RIO: A randomized controlled non-inferiority trial to test the safety of discontinuation of riociguat after balloon pulmonary angioplasty in Chronic Thrombo-embolic Pulmonary Hypertension
2024-519225-38-00Chronic thromboembolic pulmonary hypertension (CTEPH)
Amsterdam UMC Stichting
Cardiovascular Diseases
Netherlands
29/09/2025
Phase III
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
2025-520766-22-00Myotonic Dystrophy Type 1
Avidity Biosciences Inc.
Musculoskeletal Diseases
France, Denmark, Spain, Italy, Germany, Netherlands
29/09/2025
Phase III
A Phase 3b Extension Study to Evaluate the Long-Term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohnโ€™s Disease
2023-508804-39-00Ulcerative Colitis or Crohnโ€™s Disease
Takeda Development Center Americas Inc.
Digestive System Diseases
Spain, Ireland, Portugal, Poland, Belgium, Netherlands, Bulgaria, Romania, Italy, Denmark
29/09/2025
Phase II
HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanced HER2-positive breast cancer
2024-516253-49-01advanced/metastatic HER2-positive breast carcinoma
Institut Jules Bordet
Neoplasms
Belgium, Netherlands
29/09/2025
Phase II
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of SAR444336 in participants with microscopic colitis in clinical remission with budesonide.
2024-519495-83-00Digestive system diseases
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Italy, Sweden, Germany, France, Poland, Denmark, Belgium, Hungary
29/09/2025
Phase II
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly
2025-521243-20-00Acromegaly
Alexion Pharmaceuticals Inc.
Hormonal diseases
Lithuania, Romania, Denmark, Italy, Hungary, Poland, Netherlands
29/09/2025
Phase II
Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.
2025-521377-14-00Atrial fibrillation
Acesion Pharma ApS
Cardiovascular Diseases
Hungary, Italy, Denmark, Bulgaria, Poland, Netherlands, Germany
29/09/2025
Phase II
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis
2024-518821-13-00Non-cystic Fibrosis Bronchiectasis
CSL Behring LLC
Respiratory Tract Diseases
Spain, Belgium, Germany, Greece, Denmark, Netherlands, Hungary, Italy, France, Poland
26/09/2025
Phase I
CITY
2024-520294-13-00Cutaneous T-cell lymphomas (CTCL)
Assistance Publique Hopitaux De Paris
Skin and Connective Tissue Diseases
Spain, France
26/09/2025
Phase IV
A single centre parallel-group randomized control trial of Magnetic Resonance Assessment of Variations in Effects of anaesthesia on renaL perfusion in children
2025-520627-25-00Post-operative Acute Kidney Injury
Region Uppsala
Physiological processes
Sweden
26/09/2025
Phase I
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS
2024-519537-29-00Acute Myeloid Leukemia and Myelodysplastic Syndrome
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Spain
26/09/2025
Phase III
Obesity and Semaglutide in Type 1 Diabetes Therapy (OBES1TY): A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial
2025-522326-13-00Obesity defined by BMI equal to or higher than 30, Obesity โ€ฆ
Region Hovedstaden
Hormonal diseases
Denmark
26/09/2025
Phase III
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2024-517131-52-00Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lympโ€ฆ
BeOne Medicines AG
Neoplasms
France, Sweden, Czechia, Austria, Belgium, Germany, Denmark, Spain, Netherlands, Italy, Ireland, Poland
26/09/2025
Phase I/II
A phase 1/2, open label, multicenter clinical trial investigating the safety, tolerability, pharmacokinetics, and antineoplastic activity of S095035 (MAT2A inhibitor) as a single agent and in combination in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP
2025-521249-25-00MTAP-deleted advanced or metastatic solid tumors
Institut De Recherches Internationales Servier IRIS
Neoplasms
Denmark, Italy, Germany, Spain, France
26/09/2025
Phase III
A 52 week, randomized, double-blind, double dummy multinational, multicenter, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 ยตg pMDI (fixed combination of extrafine Beclomethasone Dipropionate plus Formoterol Fumarate plus Glycopyrronium Bromide) to Seretideยฎ Evohalerยฎ 125/25 ยตg pMDI (fixed combination of fluticasone propionate / salmeterol xinafoate) in adolescent subjects with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long acting รŸ2 agonists.
2024-514248-95-00Uncontrolled Asthma
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Italy, Germany, Spain
26/09/2025
Phase I
A PHASE 1/1B, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF VVD-159642 AS A SINGLE AGENT AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
2025-522148-42-00Advanced Solid Tumours
Vividion Therapeutics Inc.
Neoplasms
Spain
26/09/2025
Phase III
A multi-centre, single-arm study to demonstrate the efficacy of bone marrow allogeneic mesenchymal cells combined with biomaterial (combined ATMP) for bone healing in delayed union and non-union after long bone fractures (OrthoAlloUnion).
2025-520841-60-00Delayed consolidation or non-union long bone fracture
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda
Musculoskeletal Diseases
Spain, Italy, France, Germany
26/09/2025
Phase IV
Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed moderate-to-severe ulcerative colitis: A 52-week, multicenter, open-label, randomized controlled trial
2025-522585-72-00ulcerative colitis
Universitaetsklinikum Schleswig-Holstein AรถR
Digestive System Diseases
Germany
26/09/2025
Phase II
The effect of colchicine, on insulin sensitivity in individuals with type 1 diabetes and systemic low-grade inflammation (INS1GHT)
2025-522528-29-00Type 1 diabetes
Gentofte Hospital
Hormonal diseases
Denmark
26/09/2025
Phase II
A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B-Cell driven Diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA)
2025-523061-22-00Granulomatous Polyangiitis, Systemic Lupus Erythematosus, Sโ€ฆ
Universitaet Leipzig
Immune System Diseases
Germany
26/09/2025
Phase III
Changes in plaque characteristics after short-term statin therapy assessed with coronary CT
2025-522868-32-00Coronary Artery Disease, Cardiology, Statin Therapy, Coronaโ€ฆ
Semmelweis University
Cardiovascular Diseases
Hungary
26/09/2025
Phase I
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2024-514152-32-00Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLโ€ฆ
F. Hoffmann-La Roche AG
Neoplasms
France, Spain, Poland
25/09/2025
Phase III
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Phase III Therapeutic Superiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Diclofenac + Orphenadrine + Paracetamol to Diclofenac (Cataflamยฎ) and Orphenadrine + Paracetamol (Norgesicยฎ) in Patients with Acute Severe Low Back Pain.
2025-521578-32-00LOW BACK PAIN
Verisfield Single Member S.A.
Musculoskeletal Diseases
Greece
25/09/2025
Phase II
PK/PD of Cefadroxil in Staphylococcus Aureus Bacteremia, a preliminary study
2025-522547-17-00staphylococcus aureus bacteremia
UZ Brussel
Bacterial Infections and Mycoses
Belgium
24/09/2025
Phase IV
Pharmacokinetic study of the use of Nefopam 30 mg tablet in patients suffering from acute pain in rheumatology - NEFOPAIN kinetics
2025-521926-13-00Hospitalized patient with acute rheumatological pain, requiโ€ฆ
Centre Hospitalier Universitaire Rouen
Pathological Conditions, Signs and Symptoms
France
24/09/2025
Phase II
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME)
2025-521178-33-00Chronic Hepatitis B Virus Infection
Aligos Therapeutics Inc.
Virus Diseases
Spain, Italy, Bulgaria, Romania, France
24/09/2025
Phase II
A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients with IgAN
2025-521519-37-00IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Dโ€ฆ
Vera Therapeutics Inc.
Pathological Conditions, Signs and Symptoms
Spain, Poland
24/09/2025
Phase III
EASi-PROTKTโ„ข - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease
2025-521188-11-00hypertension, cardiovascular disease, Type 2 diabetes
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Cardiovascular Diseases
Lithuania, Netherlands, Ireland, Romania, France, Hungary, Finland, Latvia, Austria, Germany, Greece, Italy, Sweden, Denmark, Czechia, Belgium, Slovakia, Croatia, Spain, Norway, Bulgaria, Poland, Portugal
24/09/2025
Phase III
ARGX-113-2409: A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo- Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants from 12 Years to Less Than 18 Years of Age with Chronic ITP
2025-521055-23-00Chronic Idiopathic thrombocytopenic purpura
Argenx
Immune System Diseases
Lithuania, Romania, Hungary, France, Italy, Spain, Poland, Germany
24/09/2025
Phase II
TACTIC : MP0317, A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN, IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CARCINOMA A RANDOMIZED NON COMPARATIVE PROOF OF CONCEPT PHASE II STUDY
2024-520029-35-01ADVANCED BILIARY TRACT CARCINOMA
Centre Hospitalier Regional Universitaire
Digestive System Diseases
France
24/09/2025
Phase II
A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2024-520117-50-00Atopic Dermatitis
Inmagene LLC
Immune System Diseases
Czechia, Spain, Germany, Hungary, Poland
24/09/2025
Phase IV
A low-intervention prospective-retrospective study to evaluate the pharmacokinetics of elexacaftor/tezacaftor/ivacaftor combination in a Cystic Fibrosis population
2024-518785-28-00Cystic Fibrosis
IRCCS Istituto Giannina Gaslini
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy
24/09/2025
Phase III
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
2024-518206-40-00Severe hypertriglyceridemia (SHTG)
Arrowhead Pharmaceuticals Inc.
Nutritional and Metabolic Diseases
Hungary, Bulgaria, Sweden, Austria, Norway, Belgium, Croatia, Czechia, Latvia, Lithuania, Spain, Slovakia
23/09/2025
Phase III
OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women
2024-519655-28-00Premenopausal patients with high-risk HR-positive/HER2-negaโ€ฆ
Unicancer
Neoplasms
Poland, France, Italy, Greece, Spain, Ireland, Belgium
23/09/2025
Phase I/II
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
2024-516234-35-00Relapsed or Refractory B-Cell Malignancies
BeOne Medicines AG
Neoplasms
Italy, Germany, Poland
23/09/2025
Phase III
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA
2024-516411-24-00Insomnia Disorder
Vanda Pharmaceuticals Netherlands B.V., Vanda Pharmaceuticals Inc.
Nervous System Diseases
Poland, Germany
23/09/2025
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)
2024-519345-30-00IgA nephropathy
Biogen Idec Research Limited
Immune System Diseases
Greece, Portugal, Spain, Croatia, Czechia, Belgium, Bulgaria, Germany, Italy, Poland, France
23/09/2025
Phase II
Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning before Allogeneic Stem Cell Transplantation in AML, MDS/AML and higher risk MDS (Vestal)
2025-521372-62-00Acute Myeloid Leukemia (AML), Myleodyplastic Neoplasm/Acuteโ€ฆ
Universitaetsklinikum Tuebingen AรถR
Hemic and Lymphatic Diseases
Germany
23/09/2025
Phase III
A randomized, multicenter, multiple-dose, double-blind, placebo-controlled, parallel-group design, clinical endpoint bioequivalence study to evaluate the therapeutic equivalence and safety of fluticasone furoate and vilanterol inhalation powder 100 mcg/25 mcg (Sandoz) and BREOยฎ ELLIPTAยฎ (fluticasone furoate and vilanterol inhalation powder) 100 mcg/25 mcg (GlaxoSmithKline) in adult participants with asthma
2025-521565-27-00Asthma
Sandoz Private Limited
Respiratory Tract Diseases
Poland
22/09/2025
Phase I
A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A
2025-520490-38-00Haemophilia A with or without inhibitors. Proposed indicatiโ€ฆ
Novo Nordisk A/S
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Poland, Spain, Austria, Italy, Germany, Belgium, France, Portugal, Sweden
22/09/2025
Phase II
Clindamycin as an alternative to vancomycin in patients undergoing aortic cardiac surgery with extracorporeal circulation (ECC): a prospective single-center pharmacokinetic study _ CLINDAPASS
2025-521555-23-00Patients undergoing cardiac surgery with extracorporeal cirโ€ฆ
Centre Hospitalier Universitaire De Nantes
Bacterial Infections and Mycoses
France
22/09/2025
Phase II
A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis
2024-519081-49-00Moderate to severe atopic dermatitis
Novartis Pharma AG
Skin and Connective Tissue Diseases
Czechia, Netherlands, Poland, Germany, Spain, Hungary, France, Italy, Slovakia
22/09/2025
Phase I
A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors
2024-519622-20-00Advanced Solid Tumors Harboring RAS Mutation(S)
F. Hoffmann-La Roche AG
Neoplasms
Germany, Netherlands, Spain, Denmark, France, Belgium
22/09/2025
Phase II
A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE) [without IMPD-Q]
2024-517561-16-00non-small cell lung cancer
AIO-Studien gGmbH
Neoplasms
Germany
22/09/2025
Phase I
Research into new test methods to measure pain with two existing drugs (nefopam and oxycodone)
2025-522389-66-00(Chronic) pain
Centre for Human Drug Research
Nervous System Diseases
Netherlands
22/09/2025
Phase II
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO).
2025-520473-40-00Moderate to Very Severe Chronic Obstructive Pulmonary Diseaโ€ฆ
AstraZeneca AB
Respiratory Tract Diseases
Spain, Greece, Bulgaria, Germany, Denmark, Hungary, Italy, Poland
22/09/2025
Phase II
A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant Non-Small Cell Lung Cancer (NSCLC) โ€“ Subprotocol D
2025-521681-10-00Lung Cancer
Revolution Medicines Inc.
Respiratory Tract Diseases
Germany, Greece, Netherlands, Czechia, France, Austria, Denmark, Spain, Italy
22/09/2025
Phase I
An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE)
2025-520629-19-00HIV Infections
Viiv Healthcare UK Limited
Virus Diseases
Netherlands, Spain, Belgium, Denmark
22/09/2025
Phase I
A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors previously treated with other therapies.
2024-512403-39-01Advanced Solid Tumors Who Are Beyond Standard of Care
Abalos Therapeutics GmbH
Neoplasms
Spain, Germany
22/09/2025
Phase III
A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)
2025-520554-11-00Cardiovascular Disease
Amgen Inc.
Cardiovascular Diseases
Spain, Hungary, Portugal, Greece, Germany, Italy, Austria, Ireland, Romania, Slovakia, Netherlands, Czechia, Bulgaria, Denmark, France, Poland, Belgium
22/09/2025
Phase III
ADVANCE: A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy Clinical Trial Comparing Essentialeยฎ Liquid vs. Capsules for MASLD/MASH, Alcoholic Liver Disease, and Chronic Viral Hepatitis B
2025-521678-32-00Alcoholic Liver Disease, MASLD (Metabolic Dysfunction-Assocโ€ฆ
Opella Healthcare Group S.A.S.
Digestive System Diseases
Bulgaria, Germany, Poland
22/09/2025
Phase III
Remifentanil versus rocuronium for optimizing video laryngoscopy assisted tracheal intubation in patients undergoing general anaesthesia - a multicentre randomised controlled trial The ROCVIDEO trial
2025-521405-40-01Adult patients undergoing tracheal intubation using video lโ€ฆ
Nordsjaellands Hospital
Equipment and Supplies
Denmark, Sweden
22/09/2025
Phase III
A prospective, multi-centre, randomised, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges with benzydamine hydrochloride and dichlorobenzyl alcohol in the symptomatic treatment of patients suffering from acute pharyngitis
2025-521764-35-00acute pharyngitis
MEDICE Arzneimittel Puetter GmbH & Co. KG
Otorhinolaryngologic Diseases
Germany
19/09/2025
Phase II
Ipilimumab and nivolumab plus temozolomide and capecitabine for patients with chemo-refractory pMMR, MGMT silenced metastatic colorectal cancer: The MAYA2 trial
2025-521941-25-00Colorectal cancer
Odense University Hospital
Neoplasms
Denmark
19/09/2025
Phase I
A study in healthy men to find out how different doses of BI 3009947 are tolerated and how different formulations or food influence how BI 3009947 is taken up into the blood
2025-521095-66-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
19/09/2025
Phase I
A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function
2025-521502-18-00Tuberculosis
Otsuka Pharmaceutical Development & Commercialization Inc.
Respiratory Tract Diseases
Bulgaria
19/09/2025
Phase III
INCB018424-316: A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to < 18 Years Old) With Moderate Atopic Dermatitis
2024-518156-24-00Atopic Dermatitis
Incyte Corp.
Skin and Connective Tissue Diseases
France, Germany, Spain, Belgium, Italy, Hungary, Poland
18/09/2025
Phase II
STS-001: An explorative clinical study to assess the potential of intravenously administered sodium thiosulfate in subjects with primary Raynaudโ€™s phenomenon
2023-509432-25-00Raynaudโ€™s phenomenon
Universitair Medisch Centrum Groningen
Cardiovascular Diseases
Netherlands
18/09/2025
Phase III
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYOยฎ) vs Investigator Choice of Single-agent Chemotherapy as Third-line Treatment in Subjects with Advanced / Metastatic Non-Small Cell Lung Cancer (NSCLC)
2024-520164-33-00Non-Small Cell Lung Cancer
Maia Biotechnology Inc.
Neoplasms
Poland, Hungary, Romania, Spain, Portugal
18/09/2025
Phase II
Phase II RAINSPOT: a multicentric open label trial of Zolbetuximab-Paclitaxel-Ramucirumab in second line setting for CLDN18.2 positive gastro-esophageal adenocarcinoma
2025-521358-41-00CLDN18.2 positive gastro-esophageal adenocarcinoma
UZ Leuven
Neoplasms
Belgium
17/09/2025
Phase I
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjects
2024-512106-26-02Cognitive impairment
Vandria S.A.
Nervous System Diseases
France
17/09/2025
Phase I/II
A Phase 1/2 Open-label, Multi-centre, Dose-exploration Trial to Evaluate the Safety and Preliminary Efficacy of VG801 via Subretinal Injection in Treatment of Patients with Biallelic ABCA4 Mutation-Associated Retinal Dystrophy.
2024-520425-37-00Biallelic ABCA4 Mutation-Associated Retinal Dystrophy.
VeonGen Therapeutics GmbH
Eye Diseases
Germany
17/09/2025
Phase II
Standardized Dermatophagoides mix (D. pteronyssinus + D. farinae) in TBU/ml in liquid formulation for sublingual immunotherapy: Phase II, randomized dose determination clinical trial.
2025-521522-15-00Allergic rhinitis/rhinoconjunctivitis caused by dust mite aโ€ฆ
Asac Pharmaceutical Inmunology S.A., Advanced Outcomes Research S.L.
Immune System Diseases
Spain
17/09/2025
Rows per page Showing 2301–2400 of 2500
Previous 22 23 24 25 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-europe?page=24

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,479 trial records at the last sync on 24 Sep 2026, 03:17 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

How many clinical trials does CTIS hold?

CTIS held 12,479 trial records at the last sync. Of the 2,500 most recently authorised trials shown in this register, 743 are Phase III. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

→

Browse trials by member state

Spain (1015) France (884) Germany (862) Italy (739) Poland (582) Netherlands (531) Belgium (431) Czechia (331) Denmark (323) Hungary (258) Greece (233) Romania (211) Austria (208) Sweden (204) Bulgaria (199)
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.